The trial evaluated the effectiveness of AstraZeneca’s camizestrant, an investigational next-generation oral selective ...

Piper Sandler lowered the firm’s price target on Arvinas (ARVN) to $24 from $67 on narrowed vepdegestrant ESR1-mutant mBC approval, while ...

Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) ...

1 “These data from VERITAC-2 support the potential of vepdegestrant to give patients whose tumors harbor ESR1 mutations additional time without disease progression, compared [with] fulvestrant.” In ...

Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant in patients with ESR1-mutant (ESR1m) advanced or metastatic breast cancer, ...

Disney and Pixar are returning to Land of the Dead for “Coco 2.” Disney’s CEO Bob Iger announced the follow-up film during the company’s annual shareholder meeting. The sequel, which is ...

Investors have written off oral SERD developers completely after EMBER-3 and more recently VERITAC-2, but there is a big binary coming in the form of PersevERA, and if positive, it could ...

The phase 3 VERITAC-2 trial has been evaluating the candidate against AstraZeneca’s endocrine therapy Faslodex (fulvestrant) in adults with oestrogen receptor (ER)-positive, human epidermal growth ...

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings. The information provided on PharmiWeb.com is ...

You can find him on X @gamegriffin. Languages: English The Batman Part 2 is coming, but so far it's shrouded in mystery. What's the story, who's the villain, and when is it coming out? In this ...